Phase 3 trial evaluating the efficacy of intensive chemotherapy in combination with quizartinib or placebo in AML patients with FLT3–ITD mutation presented similar CRc rates (71.6% vs. 64.9%, respectively) and FLT3–ITD MRD negativity status (24.6% vs. 21.4%, respectively). This evidence concerns the gene FLT3 and acute myeloid leukemia.